Gothenburg, January 21, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the first patient in the CAR T-cell study CARMA, which evaluates the efficacy of ELC-301 against B-cell lymphoma, has been successfully treated. The one-month follow-up after treatment shows that the patient achieved a complete response with only very mild side effects. The treatment outcome will now be presented at the Cancer Crosslinks conference in Oslo on January 23.
The purpose of the CARMA study is to identify the optimal dose for treatment with the iTANK-armed CAR T-cell therapy ELC-301, which will then be tested in an additional six patients during the phase IIa part of the study. The first patient showed a complete response (CR) at the first follow-up, one month after completing treatment, with no serious side effects observed. Two more patients will be treated with the lowest dose level in the first dosing group (cohort 1). Elicera intends to report structured and consolidated results from the study as each cohort is completed. These data are expected to be presented at scientific conferences in 2025 and 2026. The exact timeline for reporting cohort data depends on the study's progress and the timing of relevant conferences.
"We can confirm that the CARMA study has started on a very positive note. The first patient has responded very well to the treatment with a complete response and only very mild side effects. We now continue the work of including additional patients to create the broader data set needed to assess the therapy's true efficacy and safety," says Gunilla Enblad, professor at the Department of Immunology, Genetics, and Pathology, senior consultant in oncology at Uppsala University Hospital, and clinical principal investigator for the CARMA study.
"We are pleased to have taken the first step in the clinical evaluation of Elicera Therapeutics' most advanced CAR T-cell therapy, ELC-301. We now look forward to continuing the CARMA study, which aims not only to validate our CAR T-cell therapy but also the company's patented gene technology platform, iTANK," says Jamal El-Mosleh, CEO of Elicera Therapeutics.
Elicera's Chief Scientific Officer and co-founder, Magnus Essand, will present the treatment outcome for the first patient in the CARMA study at the scientific conference Cancer Crosslinks, which will take place in Oslo on January 23.
Learn more about Cancer Crosslinks at: www.cancercrosslinks.com
This information is such information as Elicera Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on January 21, 2025.